NX PharmaGen   Report issue

For profit Phase 2
Founded: Louisville KY United States (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2015
NCT01445691
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

aminolevulinic acid (levulan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1